Shared Care Agreement Methylphenidate

This guidance covers the use of methylphenidate for attention deficit hyperactivity disorder in children and adolescents (6 years to less than 18 years of age). For all patients, if they are uncomfortable for any reason, they should talk to their family doctor. Form letters are available to provide written support to practices to their patients affected by these temporary changes. Coronavirus (COVID-19) Pandemic: In order to minimise the need for patients to visit personal contact centres with the NHS, a decrease in the frequency of monitoring the safety of the medicine has been introduced temporarily for certain groups of patients. The measurement thresholds remain unchanged. These amendments are set out in blue in the attached updated Directive. Please note that a separate adult guide is available here….